2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Ritu Salani, MD, MBA, discusses updates in treating endometrial cancer.
Ritu Salani, MD, MBA, director, Division of Gynecologic Oncology, professor, Obstetrics and Gynecology, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, discusses updates in treating endometrial cancer.
Immunotherapy has changed the treatment landscape of endometrial cancer and studies are evaluating approaches in the recurrence setting as well as the frontline setting, Salani says. Although trials are still being finalized and reviewed, the current results that have been seen with immunotherapy in this patient population is promising, Salani explains.
Moreover, molecular profiling is being utilized more often to inform treatment strategies in endometrial cancer, leading to more personalized medicine in the disease, Salani continues. Looking at the molecular mutations will continue to lead to the understanding of what therapies may best serve patients, Salani says. Some patients may be able to have therapy eliminated or deescalated, further eliminating unwanted toxicities and producing more favorable outcomes, Salani concludes.